Aptitude Medical Systems has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for its next-gen molecular Metrix COVID-19/Flu multiplex test.
The test represents a major advancement in accessible molecular diagnostics. It can detect and differentiate COVID-19, influenza A and B in 20 minutes. It may be used in home and CLIA-waived settings.
The Metrix COVID-19/Flu test simultaneously detects and differentiates SARS-CoV-2, influenza A virus and Influenza B virus in 20 minutes. Authorised for over-the-counter (OTC) use, it can be utilised in any environment, including at home and in CLIA-waived point-of-care (POC) settings.
"Molecular diagnostics are the gold standard for accuracy, but traditional systems are expensive, slow, and force molecular to be greatly underutilised. Metrix changes all that." said Scott Ferguson PhD, CEO of Aptitude. "We built Metrix to dramatically expand the reach of molecular diagnostics by breaking cost and accessibility barriers."
"COVID-19 and influenza are the top respiratory health threats in the United States, driving tens of millions of urgent care visits annually," said Jackson Gong PhD, COO, "Healthcare providers often find traditional molecular testing too cumbersome and cost prohibitive, and instead resort to antigen tests which offer much lower clinical value. What makes Metrix so exciting for urgent care is that it truly solves the cost burden, allowing providers to deliver better medicine and improve the financial viability of their practices, on which over half of Americans depend.” The Metrix test is currently available across the USA through Aptitude and our distribution partners in collaboration with Sekisui Diagnostics."
The Metrix COVID/Flu test is the second FDA-authorised molecular test on Aptitude’s Metrix platform. To learn more, visit www.aptitudemedical.com.